Literature DB >> 29234246

Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?

Luca Malorni1,2, Laura Biganzoli2.   

Abstract

Entities:  

Year:  2017        PMID： 29234246      PMCID： PMC5704686          DOI： 10.1159/000484259

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  15 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Authors:  John F R Robertson; Igor M Bondarenko; Ekaterina Trishkina; Mikhail Dvorkin; Lawrence Panasci; Alexey Manikhas; Yaroslav Shparyk; Servando Cardona-Huerta; Kwok-Leung Cheung; Manuel Jesus Philco-Salas; Manuel Ruiz-Borrego; Zhimin Shao; Shinzaburo Noguchi; Jacqui Rowbottom; Mary Stuart; Lynda M Grinsted; Mehdi Fazal; Matthew J Ellis
Journal:  Lancet       Date:  2016-11-29       Impact factor: 79.321

3.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

Authors:  George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; Martin Frenzel; Yong Lin; Susana Barriga; Ian C Smith; Nawel Bourayou; Antonio Llombart-Cussac
Journal:  J Clin Oncol       Date:  2017-06-03       Impact factor: 44.544

4.  Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

Authors:  John F R Robertson; Justin P O Lindemann; Antonio Llombart-Cussac; Janusz Rolski; David Feltl; John Dewar; Laura Emerson; Andrew Dean; Matthew J Ellis
Journal:  Breast Cancer Res Treat       Date:  2012-10-13       Impact factor: 4.872

5.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

Authors:  Henning Mouridsen; Mikhail Gershanovich; Yan Sun; Ramon Perez-Carrion; Corrado Boni; Alain Monnier; Justus Apffelstaedt; Robert Smith; Harm P Sleeboom; Fritz Jaenicke; Anna Pluzanska; Magdolna Dank; Dominique Becquart; Poonamalle P Bapsy; Eeva Salminen; Ray Snyder; Hilary Chaudri-Ross; Raquel Lang; Peter Wyld; Ajay Bhatnagar
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

6.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon
Journal:  Lancet Oncol       Date:  2016-03-03       Impact factor: 41.316

7.  Palbociclib and Letrozole in Advanced Breast Cancer.

Authors:  Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

8.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Authors:  Matthew P Goetz; Masakazu Toi; Mario Campone; Joohyuk Sohn; Shani Paluch-Shimon; Jens Huober; In Hae Park; Olivier Trédan; Shin-Cheh Chen; Luis Manso; Orit C Freedman; Georgina Garnica Jaliffe; Tammy Forrester; Martin Frenzel; Susana Barriga; Ian C Smith; Nawel Bourayou; Angelo Di Leo
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

9.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Authors:  Gabriel N Hortobagyi; Salomon M Stemmer; Howard A Burris; Yoon-Sim Yap; Gabe S Sonke; Shani Paluch-Shimon; Mario Campone; Kimberly L Blackwell; Fabrice André; Eric P Winer; Wolfgang Janni; Sunil Verma; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Katarina Petrakova; Lowell L Hart; Cristian Villanueva; Arlene Chan; Erik Jakobsen; Arnd Nusch; Olga Burdaeva; Eva-Maria Grischke; Emilio Alba; Erik Wist; Norbert Marschner; Anne M Favret; Denise Yardley; Thomas Bachelot; Ling-Ming Tseng; Sibel Blau; Fengjuan Xuan; Farida Souami; Michelle Miller; Caroline Germa; Samit Hirawat; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

10.  Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Authors:  N Harbeck; S Iyer; N Turner; M Cristofanilli; J Ro; F André; S Loi; S Verma; H Iwata; H Bhattacharyya; K Puyana Theall; C H Bartlett; S Loibl
Journal:  Ann Oncol       Date:  2016-03-30       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.